Calcium folinate is indicated
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
Calcium folinate is indicated
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
Calcium folinate is indicated:
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
Calcium folinate is indicated:
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
For adult patients with type 2 diabetes mellitus:
Sitavia-MET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination
of sitagliptin and metformin.
Sitavia-MET is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a
sulphonylurea.
Sitavia-MET is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled
on their maximal tolerated dose of metformin and a PPARγ agonist.
Sitavia-MET is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and
exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide
adequate glycaemic control.
Antepartum
• Induction of labour for medical reasons, e.g. in cases of Rh problems, post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia)
• Stimulation of labour in hypotonic uterine inertia
• Early stages of pregnancy as adjunctive therapy for the management of incomplete, inevitable, or missed abortion.
Postpartum
• During caesarean section, but following delivery of the child
• Prevention and treatment of postpartum uterine atony and haemorrhage
Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:
• Brain tumours - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumours.
• Multiple myeloma - in combination with glucocorticoid such as prednisone.
• Hodgkin"s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
• Non-Hodgkin"s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
Vancomycin Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of:
• Septicemia due to:
Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA), coagulase negative staphylococci, Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.
• Infective Endocarditis due to:
- Susceptible isolates of MRSA, Viridans group streptococci Streptococcus gallolyticus (previously known as Streptococcus bovis), Enterococcus species and Corynebacterium species. For enterococcal endocarditis, use Vancomycin Injection in combination with an aminoglycoside.
- Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.
Vancomycin is also indicated for early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis in combination with rifampin and an aminoglycoside.
• Skin and Skin Structure Infections due to:
Susceptible isolates of MRSA, coagulase negative staphylococci, Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.
• Bone Infections due to:
Susceptible isolates of MRSA, coagulase negative staphylococci, Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.
• Lower Respiratory Tract Infections due to:
• Susceptible isolates of MRSA.
• Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Injection and other antibacterial drugs, Vancomycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy
